Infantile hemangioma
Conditions
Interventions
Propranolol oral group / propranolol topical group / itraconazole oral group:Puerolol oral and topical, itraconazole oral
propranolol topical group :propranolol topical
itraconazole oral group:itraconazole oral
Sponsors
The Third Xiangya Hospitals Of Central South University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet the following criteria may be included in the trial: 1) Proliferation period IH; 2) children younger than 6 months, or although more than 6 months, but the tumor is still growing significantly in the near future; 3) No administration of propranolol / itraconazole in the past 4 weeks; or propranolol / oral administration of itraconazole in patients with ineffective treatment may consider intergroup switching; 4) do not merge other system diseases; 5) do not take other treatment drugs such as painkillers, anticoagulants and so on; 6) Informed consent must be obtained from the child guardian; 7) The child guardian fully understands the clinical trial and voluntarily joins, is willing to refer to the prescribed time to assist in the completion of the trial.
Exclusion criteria
Exclusion criteria: Subjects who meet one of the following conditions are not eligible for trial: 1) Participated in other clinical trials within 4 weeks prior to the start of the study 2) liver and kidney function was abnormal (ie, the index is more than twice the normal value); 3) due to the merger of other diseases need to take a variety of drug treatment or multiple / serious complications; 4) children who are not suitable for use with propranolol / itraconazole; 5) Children who are considered not suitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HemangiomaActivity Score;vascular endothelial growth factor;Blood concentration; | — |
Countries
China
Contacts
Public ContactLu Jianyun
The Third Xiangya Hospitals Of Central South University
Outcome results
None listed